// App-Quantinova.ai

3035 : TRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making

Researchers

Presenter

  • Edward Bataillard

Principal Investigators

  • Will Harris

  • Tarec Christoffer El-Galaly

  • Antonia Kwan

  • Carsten Henneges

  • Joseph N Paulson

  • Tina G Nielsen

Medical Centers

  • Imperial College, London, United Kingdom

  • Genentech, Inc., South San Francisico, CA

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

Locations

  • United Kingdom

  • United States

  • Switzerland

Companies

  • Genentech, Inc.

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

  • Diffuse large B-cell lymphoma

Biomarkers

  • TNF superfamily member 10

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Doxorubicin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved